C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4)-Pipeline Review, H2 2017

“The Report C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4)-Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. – MarketResearchReports.biz”

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4)-C-C chemokine receptor type 4 is a protein encoded by the CCR4 gene. CCR4 is expressed on Th2 T lymphocytes and is up-regulated by T cell receptor activation. This receptor also plays an important role in trafficking of dendritic cells. The CC chemokines CCL3, CCL5, CCL17 and CCL22 signal through this receptor.

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) pipeline Target constitutes close to 9 molecules. Out of which approximately 9 molecules are developed by Companies. The molecules developed by companies in Phase III, Preclinical and Discovery stages are 1, 6 and 2 respectively. Report covers products from therapy areas Oncology, Immunology, Central Nervous System and Dermatology which include indications Autoimmune Disorders, Solid Tumor, T-Cell Lymphomas, Allergies, Atopic Dermatitis, Breast Cancer, Cutaneous T-Cell Lymphoma, Epithelial Tumor, Gastric Cancer, Hematological Tumor, Kidney Cancer (Renal Cell Cancer), Mycosis Fungoides, Myelopathy, Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Sezary Syndrome, T-Cell Leukemia and Tropical Spastic Paraparesis.

Get Sample Copy Of This Report @ https://www.marketresearchreports.biz/sample/sample/1361359

The latest report C-C Chemokine Receptor Type 4-Pipeline Review, H2 2017, outlays comprehensive information on the C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

View Report @ https://www.marketresearchreports.biz/reports/1361359/c-c-chemokine-receptor-type-4-k5-5-or-cd194-or-ccr4-pipeline-review-h2-2017-market-research-reports

Scope

– The report provides a snapshot of the global therapeutic landscape for C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4)

– The report reviews C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics and enlists all their major and minor projects

– The report assesses C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics

Reasons to buy

– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

– Identify and understand the targeted therapy areas and indications for C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4)

– Identify the use of drugs for target identification and drug repurposing

– Identify potential new clients or partners in the target demographic

– Develop strategic initiatives by understanding the focus areas of leading companies

– Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics

– Devise corrective measures for pipeline projects by understanding C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) development landscape

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4)-Overview

C-C chemokine receptor type 4 is a protein encoded by the CCR4 gene. CCR4 is expressed on Th2 T lymphocytes and is up-regulated by T cell receptor activation. This receptor also plays an important role in trafficking of dendritic cells. The CC chemokines CCL3, CCL5, CCL17 and CCL22 signal through this receptor.C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4)-Therapeutics Development

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4)-Companies Involved in Therapeutics Development

Affitech A/S

AstraZeneca Plc

ChemoCentryx Inc

Corion Biotech Srl

FLX Bio Inc

Globavir Biosciences Inc

Kyowa Hakko Kirin Co Ltd

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074

Website: http://www.marketresearchreports.biz/

E: sales@marketresearchreports.biz

%d bloggers like this: